CJC-1295 (no DAC)
10mg
A modified GHRH analog without the drug affinity complex, used in endocrine signaling studies.
Bundle & save
Strength
- Ships in 24 hours
- HPLC & endotoxin verified
- Encrypted checkout
Research details
Areas of research interest
CJC-1295 without DAC is studied as a stimulator of the body's own growth hormone (GH) release. Interest centers on GH and IGF-1 secretion, body composition, and age-related GH decline. It is not approved by FDA for any use.
Overview
CJC-1295 without DAC, also called Modified GRF(1-29), is a 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). Four amino acid substitutions protect it from rapid enzymatic breakdown. Unlike the DAC version, it lacks the albumin-binding group, so its activity is much shorter.
Research summary
Shared sequence. The same modified GRF(1-29) sequence, in its DAC form, produced dose-dependent increases in GH and IGF-1 in healthy adults [1]. Most published clinical data come from that DAC version, and dedicated human studies of the no-DAC form are limited.
GHRH(1-29) research. GHRH(1-29) is the shortest fragment of natural GHRH that keeps full activity. A review of the unmodified form (sermorelin) argued that stimulating the pituitary preserves natural GH secretion patterns better than giving GH directly [2].
References
- 1. Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683
- 2. Walker RF. Clin Interv Aging. 2006. PMID: 18046908
For laboratory research use only. Not for human or veterinary use. This product is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.